Enanta Pharmaceuticals
ENTA
105 hedge funds and large institutions have $199M invested in Enanta Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 40 increasing their positions, 42 reducing their positions, and 42 closing their positions.
5.01% more ownership
Funds ownership: 95.65% → 100.66% (+5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 42
11% less capital invested
Capital invested by funds: $225M → $199M (-$25.5M)
20% less funds holding
Funds holding: 132 → 105 (-27)
64% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 42
65% less call options, than puts
Call options by funds: $18K | Put options by funds: $51K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$16.6M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.8M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.74M |
| 4 |
D.E. Shaw & Co
New York
|
+$2.58M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$11.6M |
| 2 |
Pictet Asset Management
Carouge,
Switzerland
|
-$5.82M |
| 3 |
Millennium Management
New York
|
-$2.4M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.21M |
| 5 |
HF
HRT Financial
New York
|
-$1.15M |
ENTA Hedge Fund Activity: Q4 2023 in Review
105 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q4 2023, worth a combined $199M — down 11% from $225M a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of ENTA and 15 opened new positions — a net loss of 27 holders — while 42 trimmed existing stakes and 40 added.
The largest buyer was Morgan Stanley, adding an estimated $16.6M. The largest seller was Braidwell, exiting entirely with an estimated $11.6M sold.
- 105 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q4 2023, down from 132 in Q3 2023.
- Funds reported $199M of Enanta Pharmaceuticals stock for Q4 2023, down 11% quarter-over-quarter.
- 15 funds opened new Enanta Pharmaceuticals positions in Q4 2023 and 42 closed out, a net change of -27 holders.
- The largest Enanta Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $16.6M added.
- The largest Enanta Pharmaceuticals seller in Q4 2023 was Braidwell, an estimated $11.6M sold.
Based on aggregated 13F filings for Q4 2023.